Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109368 · ClinicalTrials.gov registry record
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
A clinical trial of Homozygous Familial Hypercholesterolemia, sponsored by The Rogosin Institute.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT01109368 is a study of Homozygous Familial Hypercholesterolemia that is actively recruiting participants, run by The Rogosin Institute. The registered enrollment target is 60 participants, below the 242-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01109368, a study of Homozygous Familial Hypercholesterolemia, is actively recruiting participants, sponsored by The Rogosin Institute.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This repository will establish for the first time a system to carefully assess and monitor over time the general health and the amount of cholesterol in the arteries of U.S. children and adults with homozygous familial hypercholesterolemia (hoFH). Patients with this very rare disorder have very high blood levels of cholesterol from birth due to the inheritance of an abnormal gene from each parent. As a result, if untreated, heart attacks and sudden death occur in childhood. Treatments such as LDL-apheresis and liver transplant will lower the cholesterol level, but the best treatment and the best way to monitor the effect of the treatment on the arteries are unknown. The collection of clinical data and blood for analysis of known and yet-to-be discovered markers and predictors of arterial disease will yield new information about the natural history of the disorder and response to treatment. The repository will greatly aid the development of specific protocols that seek to learn more about this disease and new therapies.
Conditions Studied
Study Locations (1)
New York
- The Rogosin Institute, Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-06 |
| Est. Completion | 2030-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109368
The ClinicalTrials.gov registry entry for NCT01109368 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 6 other Homozygous Familial Hypercholesterolemia trials with a reported enrollment target (75% lower). The listed sponsor is The Rogosin Institute, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Homozygous Familial Hypercholesterolemia appearing as the primary indexed condition, and to 0 interventions.
NCT01109368 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01109368 about?
NCT01109368 is a clinical study titled "The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository". This repository will establish for the first time a system to carefully assess and monitor over time the general health and the amount of cholesterol in the arteries of U.S. children and adults with homozygous familial hypercholesterolemia (hoFH). Patients with this very rare disorder have very high...
What is the current status of trial NCT01109368?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2010-06. Estimated completion is 2030-05.
What conditions does trial NCT01109368 study?
This clinical trial studies the following conditions: Homozygous Familial Hypercholesterolemia.
Who is sponsoring clinical trial NCT01109368?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01109368 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homozygous Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HoFH, the International Clinical Collaborators Registry
RECRUITING
-
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
RECRUITING · Phase 3
-
LOWER: Lomitapide Observational Worldwide Evaluation Registry
RECRUITING
-
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
COMPLETED · Phase 2
-
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.